PharmaPoint:
Meningococcal Vaccines US & UK Drug Forecast and Market Analysis to 2022.
Meningococcal disease is an acute infection caused by the gram-negative
bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms
makes prompt and effective diagnosis and treatment nearly impossible. For these
reasons the meningococcal disease space is dominated by vaccines. Currently,
tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo,
account for the vast majority of global sales, with the US & UK adolescent
market being the key target segment. GlobalData expects growth in the
meningococcal vaccines market to be primarily driven by the launch of serotype
B vaccines, which address a critical unmet need in the treatment landscape.
Vaccines that better protect infants and/or provide a longer duration of
immunity also have an opportunity to seize market share during 2012-2022.
US Meningococcal Vaccines Drug
Market Analysis to 2022
The
MenACWY patient share to remain stagnant because of the market’s high level of
maturity. In contrast, the MenB vaccine market appears poised to take off in
the US. GlobalData anticipates that Pfizer will target adolescents with its
MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s
current immunization recommendations (CDC, 2013b). On the other hand, the
reluctance of policymakers to implement a routine infant program that does not
offer serogroup B protection poses a challenge to companies that have targeted
this age segment, such as GSK.
Complete Report Copy@ Complete
Report Copy@ http://www.rnrmarketresearch.com/pharmapoint-meningococcal-vaccines-us-drug-forecast-and-market-analysis-to-2022-market-report.html
Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=105682
UK Meningococcal Vaccines Drug
Market Analysis to 2022
Relative
patient share for the three MenC conjugate vaccines will shift due to changes
being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due
to its elimination from the single primary dose, with patient share expected to
be made up by Menjugate and NeisVac-C.
Complete Report Copy@ Complete
Report Copy@ http://www.rnrmarketresearch.com/pharmapoint-meningococcal-vaccines-uk-drug-forecast-and-market-analysis-to-2022-market-report.html
Order / Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=105683
Scope
- Overview
of Meningococcal Vaccines including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed
information on the key drugs in the US including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales
forecast for the top drugs in the US from 2012-2022.
- Analysis
of the impact of key events as well the drivers and restraints affecting the US
Meningococcal Vaccines market.
Reasons to buy
- Understand
and capitalize by identifying products that are most likely to ensure a robust
return
- Stay
ahead of the competition by understanding the changing competitive landscape
for Meningococcal Vaccines
- Effectively
plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
- Make
more informed business decisions from insightful and in-depth analysis of drug
performance
- Obtain
sales forecast for drugs from 2012-2022 in the US
